Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2022-09-12 Interim / Quarterly Rep…
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
ERYTECH PHARMA - RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2022
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport Financier Semestriel' (Interim Financial Report) for the period ending June 30, 2022. It contains a formal declaration by the CEO, a detailed management report (Rapport d'activité) covering business developments, and financial tables (Résultats) comparing the first half of 2021 and 2022. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-12 French
ERYTECH Provides Business and Financial Update for the First Half of 2022
Interim / Quarterly Report Classification · 1% confidence The document is a press release titled 'ERYTECH Provides Business and Financial Update for the First Half of 2022'. It contains detailed financial tables, business highlights, and management commentary regarding the company's performance for the first half of the fiscal year. While it mentions that the full 'Half-Year financial report' has been filed separately with the AMF, this document itself provides the substantive financial data and analysis for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than a mere announcement (RPA). H2 2022
2022-09-12 English
ERYTECH fait le point sur ses activités et publie ses résultats semestriels 2022
Interim / Quarterly Report Classification · 1% confidence The document is a press release from ERYTECH Pharma announcing its semi-annual financial results for the first half of 2022. It includes a summary of business activities, strategic updates, and a detailed financial table (income statement and cash position). While it mentions that the full financial report has been filed with the AMF, the document itself provides the substantive financial data and management commentary for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than just an announcement (RPA). H1 2022
2022-09-12 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2022
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 juillet 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of July 31, 2022). It explicitly references Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF). This type of mandatory monthly disclosure in France regarding the total number of shares and voting rights is a specific regulatory filing. It does not fit the definitions for Annual Report (10-K), Earnings Release (ER), or Interim Report (IR). Since it is a specific regulatory disclosure concerning share capital structure and voting rights, and not a general announcement of a report publication (RPA) or a general miscellaneous filing (RNS), it most closely aligns with a specific regulatory disclosure. Given the options, this type of mandatory periodic disclosure about share capital structure is often categorized under general regulatory filings or specific capital structure updates. However, none of the codes perfectly match a 'Monthly Voting Rights Disclosure'. Comparing the definitions, it is a mandatory regulatory filing concerning capital structure. Since 'SHA' is for Share Issue/Capital Change (which this is related to, but it's a periodic report *of* the structure), and 'RNS' is the general regulatory fallback, I must choose the best fit. This is a routine, mandatory disclosure of the capital base. In many classification schemes, these monthly voting rights reports fall under general regulatory announcements or specific capital structure reports. Given the provided list, 'SHA' (Share Issue/Capital Change) is related but less accurate than a general regulatory filing if a specific code for voting rights isn't present. Since it is a formal, periodic regulatory filing required by the AMF, 'RNS' (Regulatory Filings - general fallback) is the most appropriate category when a specific code for 'Monthly Voting Rights Disclosure' is missing, as it is a mandatory regulatory submission.
2022-09-06 French
Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2022
Regulatory Filings Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital - August 31, 2022." It explicitly references Article 223-16 of the French AMF regulation and provides a table detailing the evolution of total shares and voting rights over several months, culminating in the August 31, 2022 figure. This type of regular disclosure regarding the total number of shares and voting rights is a specific regulatory requirement, often falling under general regulatory announcements or specific share/capital change disclosures. Since it is a monthly update on the total share capital structure and voting rights, it is most closely related to 'Share Issue/Capital Change' (SHA) or a general 'Regulatory Filing' (RNS). Given the specific nature of reporting total voting rights monthly, it is a mandatory regulatory disclosure. While it touches upon share capital, it is not an announcement of a specific transaction (like a buyback or new issue), but rather a periodic status report. In many contexts, these monthly voting rights disclosures are categorized under general regulatory updates or specific capital structure notifications. Given the options, 'SHA' (Share Issue/Capital Change) is plausible as it relates to the capital base, but 'RNS' (Regulatory Filings) is a safer fallback for mandatory, periodic regulatory reporting that doesn't fit a transactional category. However, since it directly reports on the composition of the share capital and voting rights, which is a key component of capital structure reporting, SHA is a strong candidate. Let's re-evaluate the definitions. SHA is for 'Announcement regarding new share issues, stock splits, or other capital changes.' This is a report *about* the existing capital structure. Given the highly specific nature of the data (voting rights calculation based on AMF rules), it fits best as a specific regulatory disclosure. If a more specific code existed for 'Total Voting Rights Disclosure', that would be chosen. Lacking that, and noting that it is a mandatory periodic report, RNS is the most appropriate general regulatory category, although SHA is related to the subject matter. Considering the context of mandatory periodic reporting on capital structure components, RNS (Regulatory Filings) is the most encompassing and safest classification for this type of routine regulatory update that isn't a major event like an earnings release or a specific transaction.
2022-09-06 English
ERYTECH Provides Regulatory Update
Regulatory Filings Classification · 1% confidence The document is titled 'ERYTECH Provides Regulatory Update' and details a decision to stop pursuing a BLA submission for Graspa® based on feedback from the U.S. Food and Drug Administration (FDA). It discusses clinical trials, regulatory feedback (iPSP, BLA submission), and future strategic options. This content is characteristic of an announcement regarding regulatory progress, setbacks, or strategic shifts related to drug development, which often falls under general regulatory updates or investor relations communications. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a formal legal filing, it best fits the category of a general regulatory announcement or an update that doesn't fit other specific codes. Given the focus on FDA feedback and regulatory decisions, 'Regulatory Filings' (RNS) is the most appropriate general category, as it serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes like LTR (Legal Proceedings) or ER (Earnings Release). The length (7871 chars) is substantial enough that it is the primary communication, not just an announcement of a report (RPA).
2022-08-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.